ImageneBio, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

IMA$3.81-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
License revenue	$—	$—	$—	$800
Operating expenses:
Research and development	6,669	5,653	12,630	9,693
General and administrative	5,115	1,705	11,233	4,460
Total operating expenses	11,784	7,358	23,863	14,153
Loss from operations	(11,784)	(7,358)	(23,863)	(13,353)
Other income (expense):
Interest income (expense)	1,248	(236)	2,377	(313)
Other income, net	374	9	715	4
Total other income (expense), net	1,622	(227)	3,092	(309)
Loss before income taxes	(10,162)	(7,585)	(20,771)	(13,662)
Income tax expense	(16)	—	(26)	—
Net loss	(10,178)	(7,585)	(20,797)	(13,662)
Accretion of redeemable convertible preferred shares	—	(3,149)	—	(6,200)
Net loss attributable to common stockholders	$(10,178)	$(10,734)	$(20,797)	$(19,862)
Net loss per common share, basic and diluted	$(0.63)	$(4.46)	$(1.52)	$(8.26)
Weighted-average common shares outstanding, basic and diluted	16,161,721	2,406,516	13,700,170	2,405,680
Comprehensive loss:
Net loss	$(10,178)	$(7,585)	$(20,797)	$(13,662)
Other comprehensive loss:
Unrealized loss on marketable securities	(34)	—	(138)	—
Foreign currency translation adjustment	—	(17)	—	(26)
Total comprehensive loss	$(10,212)	$(7,602)	$(20,935)	$(13,688)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.